New combo shot shows promise for obesity weight loss
NCT ID NCT04969939
First seen Jan 11, 2026 · Last updated Apr 24, 2026 · Updated 9 times
Summary
This study tested whether adding a new medicine (NNC0165-1875) to the existing weight-loss drug semaglutide helps people with obesity lose more weight. About 120 adults with a BMI between 30 and 45 took part. Participants received either the new medicine plus semaglutide or a placebo plus semaglutide, given as injections twice a week for 26 weeks. The main goals were to check safety and measure weight change.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AMC Community Endocrinology
Albany, New York, 12206, United States
-
Accellacare
Wilmington, North Carolina, 28401, United States
-
Altasciences Clinical Kansas, Inc.
Overland Park, Kansas, 66212, United States
-
Anaheim Clinical Trials, LLC
Anaheim, California, 92801, United States
-
Chrysalis Clinical Research
St. George, Utah, 84790, United States
-
Coastal Carolina Res Ctr.
North Charleston, South Carolina, 29405, United States
-
Diablo Clinical Research, Inc.
Walnut Creek, California, 94598, United States
-
East West Med Res Inst
Honolulu, Hawaii, 96814, United States
-
Endo Res Solutions Inc
Roswell, Georgia, 30076, United States
-
Evanston Premier Hlthcr Res
Skokie, Illinois, 60077, United States
-
Health Res of Hampton Roads
Newport News, Virginia, 23606, United States
-
Jacksonville Ctr For Clin Res
Jacksonville, Florida, 32216, United States
-
L-MARC Research Center
Louisville, Kentucky, 40213, United States
-
Medical Uni of SC Charleston
Charleston, South Carolina, 29425, United States
-
NYC Research, Inc.
New York, New York, 10016, United States
-
National Clin Res Inc.
Richmond, Virginia, 23294, United States
-
PharmQuest Life Sciences LLC
Greensboro, North Carolina, 27408, United States
-
Profil Institute For Clinical Research Inc
Chula Vista, California, 91911, United States
-
Selma Medical Associates
Winchester, Virginia, 22601-3834, United States
-
Soltero Cardiovascular Research Center
Dallas, Texas, 75226, United States
-
Texas Diabetes & Endocrinology, P.A._Austin
Austin, Texas, 78749, United States
-
Texas Diabetes & Endocrinology, P.A._Austin
Round Rock, Texas, 78681, United States
-
Univ of Alabama Birmingham
Birmingham, Alabama, 35294, United States
-
Velocity Clin Res Los Angeles
Los Angeles, California, 90017, United States
-
Washington Cntr Weight Mgmt
Arlington, Virginia, 22206, United States
Conditions
Explore the condition pages connected to this study.